Guidance Issued on How IRA Inflation Rebates and Maximum Fair Price Impact Medicaid AMP and Best Price
January 23, 2023 | |
Guidance Issued on How IRA Inflation Rebates and Maximum Fair Price Impact Medicaid AMP and Best Price
The Center for Medicaid and CHIP Services (CMCS) issued manufacturer guidance that addresses the impact of certain changes on pricing metrics for drug manufacturer covered outpatient drugs (CODs) required to be reported under the Medicaid Drug Rebate Program (MDRP). The guidance addresses how each of the following policy changes impact a manufacturersā€™ average manufacturer price (AMP) and Medicaid best price:… (Slifer, January 23, 2023) #Prescription Drugs
